Type 3 Diabetes: A Metabolic Intersection in Palliative Care

In the evolving landscape of metabolic disorders, the term “Type 3 Diabetes” has emerged as a provocative and multifaceted label—one that resonates in two vastly different yet clinically relevant contexts. While not officially recognized by the American Diabetes Association, “Type 3 Diabetes” is used informally to describe both Alzheimer’s disease and pancreatogenic diabetes, also known as Type 3c diabetes. For palliative care professionals, understanding both of these definitions is essential, as they carry significant implications for symptom management, prognostication, and hospice eligibility.

Type 3 Diabetes and the Alzheimer’s Hypothesis: A Brain in Metabolic Crisis

The most widely circulated interpretation of Type 3 Diabetes equates it with Alzheimer’s disease—a hypothesis supported by increasing evidence of insulin resistance in the central nervous system. Researchers have observed that insulin, long thought of as a peripheral hormone involved in glucose regulation, also plays a critical role in the brain’s neuronal survival, synaptic plasticity, and cognitive function. When insulin signaling is impaired, a cascade of neurodegenerative events may be triggered, including amyloid-beta accumulation, tau phosphorylation, mitochondrial dysfunction, and neuroinflammation.

In this paradigm, Alzheimer’s disease is framed not merely as a degenerative condition but as a cerebral manifestation of diabetes—a metabolic encephalopathy in which glucose metabolism in the brain is severely disrupted. The term “Type 3 Diabetes” emerged from this line of thinking, highlighting the overlap between metabolic syndrome, Type 2 diabetes, and neurodegeneration.

While the hypothesis remains investigational, it offers compelling clinical insight. For palliative care clinicians, it underscores the need to consider metabolic dysfunction in the progression of dementia. Poor glycemic control can exacerbate cognitive decline, behavioral disturbances, and functional loss. Conversely, overly aggressive diabetes management in patients with advanced dementia can lead to hypoglycemia, confusion, agitation, and even falls. In such cases, the goals of care must pivot from tight metabolic control to a strategy centered on patient comfort and safety.

In patients with end-stage dementia, hospice eligibility is guided by clear functional criteria: a Functional Assessment Staging Tool (FAST) score of 7c or greater, progressive dysphagia, profound dependency in activities of daily living, and evidence of recent clinical decline. If these are met, and a concurrent diagnosis of Type 2 diabetes is present, the “Type 3” lens may help explain the interplay between glucose dysregulation and accelerated cognitive decline—reinforcing the appropriateness of hospice referral.

Type 3c Diabetes: Pancreatogenic Diabetes and End-Stage Pancreatic Disease

The second and clinically recognized interpretation of Type 3 Diabetes—Type 3c or pancreatogenic diabetes—arises from structural and functional damage to the pancreas. This form of diabetes occurs secondary to diseases of the exocrine pancreas, such as chronic pancreatitis, pancreatic cancer, cystic fibrosis, hemochromatosis, and pancreatic surgery. In contrast to Type 1 and Type 2 diabetes, Type 3c involves deficiencies not only in insulin but also in glucagon, somatostatin, and pancreatic polypeptide, leading to a particularly brittle and difficult-to-manage glycemic state.

Pancreatic cancer patients are especially vulnerable to Type 3c diabetes, and its presence may herald the terminal phase of illness. In palliative care, this subtype of diabetes poses several challenges: unpredictable glucose swings, risk of profound hypoglycemia due to glucagon deficiency, and coexisting malabsorption due to exocrine insufficiency. These patients often experience weight loss, nausea, diarrhea, and cachexia, making glycemic control both difficult and clinically less relevant.

In hospice settings, the management of Type 3c diabetes must align with goals of care. This includes liberalizing the diet, deprescribing oral hypoglycemics (especially sulfonylureas, metformin, and SGLT2 inhibitors), and using insulin only when necessary for symptom relief. Pancreatic enzyme replacement therapy (PERT) may still be beneficial for comfort, reducing bloating, steatorrhea, or early satiety. Aggressive blood sugar monitoring is often neither feasible nor necessary in the home or nursing home setting, and targets should be relaxed—generally aiming to avoid symptomatic hyperglycemia rather than achieve normoglycemia.

Hospice eligibility in Type 3c diabetes should be considered when pancreatic cancer or end-stage pancreatitis is present, especially in the setting of poor nutritional intake, functional decline, recurrent hospitalizations for glycemic crises or infection, and a Karnofsky or Palliative Performance Score of 40% or lower. The presence of both endocrine and exocrine pancreatic failure is a strong predictor of short-term mortality.

Case Vignette

Mr. X, a 68-year-old male with a history of chronic pancreatitis and newly diagnosed stage IV pancreatic adenocarcinoma, was referred to hospice for symptom management. He presented with severe cachexia (BMI 17), poorly controlled diabetes despite insulin therapy, and frequent episodes of symptomatic hypoglycemia. He was also suffering from steatorrhea, nausea, and profound fatigue. His hemoglobin A1c had fallen from 8.3% to 6.4% over three months, largely due to malnutrition and decreased oral intake.

Upon hospice admission, all oral hypoglycemics were discontinued, and his insulin regimen was simplified to once-daily glargine for comfort-based glycemic control. PERT was initiated to ease digestive symptoms, and his diet was liberalized to encourage intake of preferred foods. The team focused on minimizing invasive monitoring and maximizing quality of life.

Over the following weeks, Mr. L stabilized metabolically, gained some weight with support, and was able to enjoy small meals with his family. His glucose levels remained elevated but asymptomatic. He died peacefully at home six weeks after enrollment. His case exemplifies the unique metabolic challenges posed by Type 3c diabetes and the importance of aligning diabetes care with palliative goals.

Clinical Management Principles Across Both Forms

Whether one is dealing with “Type 3 Diabetes” as a metaphor for insulin-resistant Alzheimer’s disease or as a recognized metabolic complication of pancreatic disease, certain principles remain central in palliative care:

- Avoid overtreatment: Tight glycemic control increases the risk of hypoglycemia and contributes little to quality of life in the terminal phase.

- Deprescribe when appropriate: Oral hypoglycemics with low benefit-to-risk ratios should be discontinued. Insulin should be simplified or tapered unless clearly needed.

- Support nutritional comfort: Liberalize diets. Consider comfort feeding and allow preferred foods to enhance patient satisfaction.

- Educate families: Caregivers often associate hyperglycemia with poor outcomes, and education about appropriate glycemic targets in palliative care is critical to setting expectations.

- Reinforce prognosis and goals: The presence of brittle diabetes in the context of advanced neurological or pancreatic disease often signifies limited survival. Clear conversations about goals of care, hospice enrollment, and comfort priorities are essential.

References:

1. de la Monte, S. M., & Wands, J. R. (2008). Alzheimer's Disease is Type 3 Diabetes–Evidence Reviewed. Journal of Diabetes Science and Technology, 2(6), 1101–1113.  

2. Andersen, D. K., Korc, M., Petersen, G. M., et al. (2017). Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes, 66(5), 1103–1110.  

3. American Diabetes Association. (2023). Standards of Medical Care in Diabetes. Diabetes Care, 46(Supplement_1).  

4. National Hospice and Palliative Care Organization (NHPCO). (2024). Hospice Eligibility Guidelines.  

5. Angelo, Mark, Charles Ruchalski, and Barbara J. Sproge. "An approach to diabetes mellitus in hospice and palliative medicine." Journal of Palliative Medicine 14.1 (2011): 83-87.